| 영문 | heparin | 한글 | 헤파린 |
|---|---|---|---|
| 설명 | 혈액 응고를 막는 작용을 하는 다당류의 황산에스테르. 고등동물의 각종 조직에 널리 분포되어 있으며, 수술 후의 혈전증을 막는 데 쓴다. 혈액응고란 지혈의 한 과정으로 섬유소란 물질을 만들어 내는 과정이다. 이 섬유소는 손상된 혈관의 부위에 작용하여 여러 가지 세포들을 얽어 묶는 역할을 하여 결국 손상된 혈관에서 혈액의 소실을 막는다. 이 섬유소는 트롬빈에 의해 섬유소원에서 전환된다. 헤파린이라는 물질은 이 트롬빈을 억제하는 항트롬빈을 활성화하는 물질이다. |
||
| BH | base hospital; benzalkonium and heparin; bill of health; birth history; Bishop-Harman [instruments];... |
|---|---|
| CH | case history; Chediak-Higashi [syndrome]; chiasma; Chinese hamster; chloral hydrate; cholesterol; Ch... |
| GBH | gamma-benzene hexachloride; graphite benzalkonium-heparin |
| HAREM | heparin assay rapid easy method |
| HARM | heparin assay rapid method |
| LMW heparin | Low Molecular Weight heparin |
|---|---|
| CCA | Calcium channel antagonists |
| H(2)RA | H(2) receptor antagonists |
| LTRA | Leukotriene receptor antagonists |
| AIIRA | angiotensin II receptor antagonists |
| heparin antagonists | Coagulant substances inhibiting the anticoagulant action of heparin. (12 Dec 1998) |
|---|
| heparin | <drug> Sulphated mucopolysaccharide, found in granules of mast cells, that inhibits the action of thrombin on fibrinogen by potentiating antithrombins, thereby interfering with the blood clotting cascade. Platelet factor IV will neutralise heparin. (18 Nov 1997) |
|---|---|
| heparin binding growth factor | <growth factor> Acidic fibroblast growth factor (alpha FGF, HBGF 1) and basic FGF (beta FGF, HBGF 2) are the two founder members of a family of structurally related growth factors for mesodermal or neuroectodermal cells. Synonym: heparin binding growth factor. Acronym: FGF (18 Nov 1997) |
| heparin cofactor II | <chemical> A sulfated plasma protein with the mw of approximately 66kda. The protein is an inhibitor of thrombin in plasma that is activated by dermatan sulfate or heparin. It is a member of the serpin superfamily. Pharmacological action: serine proteinase inhibitors. Chemical name: Heparin cofactor II (12 Dec 1998) |
| heparin complement | The protein component of heparin in blood. (05 Mar 2000) |
| heparin eliminase | <enzyme> An enzyme of the isomerase class that catalyses the eliminative cleavage of polysaccharides containing 1,4-linked d-glucuronate or l-iduronate residues and 1,4-alpha-linked 2-sulfoamino-2-deoxy-6-sulfo-d-glucose residues to give oligosaccharides with terminal 4-deoxy-alpha-d-gluc-4-enuronosyl groups at their non-reducing ends. Chemical name: heparin lyase Registry number: EC 4.2.2.7 (12 Dec 1998) |
| heparin-glucosamine 3-O-sulfotransferase | <enzyme> Reaction: 3'-phosphoadenylylsulfate + heparin-glucosamine = adenosine 3',5'-bisphosphate + heparin glucosamine 3-o-sulfate Registry number: EC 2.8.2.23 Synonym: glucosaminyl 3-o-sulfotransferase, d-glucosaminyl 3-o-sulfotransferase (26 Jun 1999) |
| heparin, low-molecular-weight | <chemical> Heparin fractions with a molecular weight usually between 4000 and 6000 kD. These low-molecular-weight fractions are effective antithrombotic agents. Their administration reduces the risk of haemorrhage, they have a longer half-life, and their platelet interactions are reduced in comparison to unfractionated heparin. They also provide an effective prophylaxis against postoperative major pulmonary embolism. Pharmacological action: anticoagulant, fibrinolytic agent. (12 Dec 1998) |
| heparin lyase | <enzyme> An enzyme of the isomerase class that catalyses the eliminative cleavage of polysaccharides containing 1,4-linked d-glucuronate or l-iduronate residues and 1,4-alpha-linked 2-sulfoamino-2-deoxy-6-sulfo-d-glucose residues to give oligosaccharides with terminal 4-deoxy-alpha-d-gluc-4-enuronosyl groups at their non-reducing ends. Chemical name: heparin lyase Registry number: EC 4.2.2.7 (12 Dec 1998) |
| heparin unit | The quantity of heparin required to keep 1 ml of cat's blood fluid for 24 hr at 0캜; it is equivalent approximately to 0.002 mg of pure heparin. Synonym: Howell unit. (05 Mar 2000) |
| adrenergic alpha-antagonists | Drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma. (12 Dec 1998) |
| adrenergic antagonists | Drugs that bind to but do not activate adrenergic receptors. Adrenergic antagonists block the actions of the endogenous adrenergic transmitters epinephrine and norepinephrine. (12 Dec 1998) |
| adrenergic beta-antagonists | Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrythmias, angina pectoris, glaucoma, migraine headaches, and anxiety. (12 Dec 1998) |
| aldosterone antagonists | Compounds which inhibit or antagonise the biosynthesis or actions of aldosterone. (12 Dec 1998) |
| androgen antagonists | Compounds which inhibit or antagonise the biosynthesis or actions of androgens. (12 Dec 1998) |
| gaba antagonists | Drugs that bind to but do not activate gaba receptors, thereby blocking the actions of endogenous gaba or gaba agonists. (12 Dec 1998) |
Synonyms : Antagonists, Heparin
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|